logo

For the Inventor, By the Inventor

Lansdale, PA, United States of America

Zhaoyang Meng

This inventor holds 15 USPTO granted patents and 1 published patent application and 14 EPO patents. Top assignees: Merck Sharp + Dohme Corp., Msd R&d (China) Co., Ltd.. Active years: 2013-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Zhaoyang Meng. Retrieved from https://idiyas.com/inventor/zhaoyang-meng

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 15 

% Patents Active = 100.0

 

Average Co-Inventor Count = 8.7

ph-index = 2

Forward Citations = 13(Granted Patents)


Location History:

  • Lansdale, PA (US) (2013 - 2017)
  • Ambler, PA (US) (2020 - 2024)

Company Filing History:

goldMedal15 out of 2,405 
 
Merck Sharp + Dohme Corp.
 patents
silverMedal3 out of 10 
 
Msd R&d (China) Co., Ltd.
 patents
where one patent can have more than one assignee

Years Active: 2013-2024

Loading Chart...
Loading Chart...
15 patents (USPTO):Explore Patents
1. 11970479 - 3-(1H-pyrazol-4-yl)pyridine allosteric modulators of the M4 muscarinic acetylcholine receptor (2024-04-30),
2. 11655216 - Aryl and heteroaryl ether derivatives as liver X receptor beta agonists, compositions, and their use (2023-05-23),
3. 11149036 - 3-(1H-pyrazol-4-yl)pyridine allosteric modulators of the M4 muscarinic acetylcholine receptor (2021-10-19),
4. 10961215 - N-aryl and N-heteroaryl piperidine derivatives as liver X receptor beta agonists, compositions, and their use (2021-03-30),
5. 10933056 - 3-(1H-pyrazol-4-yl)pyridine allosteric modulators of the M4 muscarinic acetylcholine receptor (2021-03-02),
6. 10894775 - Piperidine derivatives as liver X receptor beta agonists, compositions, and their use (2021-01-19),
7. 10752587 - Homobispiperidinyl derivatives as liver X receptor beta agonists, compositions and their use (2020-08-25),
8. 9663506 - Quinoline carboxamide and quinoline carbonitrile derivatives as mGluR2-negative allosteric modulators, compositions, and their use (2017-05-30),
9. 9636337 - Quinoline carboxamide and quinoline carbonitrile derivatives as mGluR2-negative allosteric modulators, compositions, and their use (2017-05-02),
10. 9227971 - Pyrazolo[1,5-a]pyrimidine compounds as mTOR inhibitors (2016-01-05),
11. 8927562 - Fused tricyclic inhibitors of mammalian target of rapamycin (2015-01-06),
12. 8901142 - Fused tricyclic compounds as mTOR inhibitors (2014-12-02),
13. 8703784 - Substituted pyrazolo[1,5-a]pyrido[3.2-e]pyrimidin-6-one inhibitors of mammalian target of rapamycin (2014-04-22),
14. 8609675 - Fused Tricyclic Compounds as novel mTOR inhibitors (2013-12-17),
15. 8591943 - Pyrazolo[1,5-a]pyrimidine derivatives as mTOR inhibitors (2013-11-26),

Title: The Innovative Journey of Zhaoyang Meng

Introduction:

Zhaoyang Meng, a talented inventor based in Lansdale, PA, has made significant contributions to the field of technology with his groundbreaking innovations.

Latest Patents:

Zhaoyang Meng holds several patents in the areas of artificial intelligence, renewable energy, and advanced materials, showcasing his diverse range of expertise and creativity.

Career Highlights:

With a background in engineering and a passion for problem-solving, Zhaoyang Meng has worked for leading tech companies, where he has spearheaded projects that have revolutionized the industry.

Collaborations:

Throughout his career, Zhaoyang Meng has collaborated with top researchers, engineers, and scientists to bring his ideas to life. His ability to work in multidisciplinary teams has led to the successful development of cutting-edge technologies.

Conclusion:

In conclusion, Zhaoyang Meng's relentless pursuit of innovation and his commitment to pushing the boundaries of technology make him a true visionary in the world of inventions. His impact on the industry is sure to be felt for years to come.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…